0001562180-20-004358.txt : 20200609 0001562180-20-004358.hdr.sgml : 20200609 20200609161735 ACCESSION NUMBER: 0001562180-20-004358 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200605 FILED AS OF DATE: 20200609 DATE AS OF CHANGE: 20200609 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GOWEN MAXINE CENTRAL INDEX KEY: 0001280044 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36352 FILM NUMBER: 20952021 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akebia Therapeutics, Inc. CENTRAL INDEX KEY: 0001517022 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208756903 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 245 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-871-2098 MAIL ADDRESS: STREET 1: 245 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2020-06-05 false 0001517022 Akebia Therapeutics, Inc. AKBA 0001280044 GOWEN MAXINE C/O AKEBIA THERAPEUTICS, INC. 245 FIRST STREET CAMBRIDGE MA 02142 true false false false Common Stock 2020-06-05 4 A false 13700.00 0.00 A 28700.00 D Common Stock 2020-06-08 4 S false 4567.00 12.05 D 24133.00 D Stock Option (Right to buy) 11.96 2020-06-05 4 A false 20100.00 0.00 A 2021-06-05 2030-06-05 Common Stock 20100.00 20100.00 D The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "RSUs"). 100% of the RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of 100% of the Reporting Person's restricted stock units granted on June 6, 2019. Represents an option to purchase shares of the Issuer's common stock granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. /s/ Nicole R. Hadas, attorney-in-fact for Maxine Gowen 2020-06-09